C12N 2710/16121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/16121 (Viruses as such) appears on 26 US grants and 37 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 37
- Assignees
- 24
- Inventors
- 59
- Latest grant
- 1 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 3 |
| 2014 | 1 | 4 |
| 2015 | 1 | 2 |
| 2016 | 1 | 3 |
| 2017 | 2 | 2 |
| 2018 | 2 | 2 |
| 2019 | 1 | 4 |
| 2020 | 5 | 1 |
| 2021 | 0 | 9 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 4 | 1 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene-drive in DNA viruses1 Jul 2025US 12,344,837 B2Buck Institute for Research on Aging
- Simian adenoviral vectors with two expression cassettes31 Dec 2024US 12,180,512 B2Glaxosmithkline Biologicals SA
- Viral particle-based vaccine21 May 2024US 11,986,521 B2Vakzine Projekt Management GmbH
- Compositions of and methods for in vitro viral genome engineering27 Feb 2024US 11,913,032 B2C3J Therapeutics, Inc.
- Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof2 Jan 2024US 11,859,199 B2Glaxosmithkline Biologicals SA
- Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells11 Jun 2026US 2026/0158087 A1Mayo Foundation for Medical Education and Research
- Engineered murine cytomegalovirus-derived tool virus, method of producing the same and applications thereof27 Nov 2025US 2025/0361526 A1Wuhan Institute of Virology, Chinese Academy of Sciences
- Gene-drive in dna viruses11 Sep 2025US 2025/0283069 A1Buck Institute for Research on Aging
- Simian adenoviral vectors with two expression cassettes21 Mar 2024US 2024/0093161 A1Glaxosmithkline Biologicals SA
- Methods and materials for assessing and treating cmv infections23 Feb 2023US 2023/0057542 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Recombinant human cytomegalovirus vaccine22US 5,720,957 AAmerican Cyanamid Company · 1998
- Cells transformed or transfected with HCMV US2 gene12US 5,908,780 AAmerican Cyanamid Company · 1999
- CMV glycoproteins and recombinant vectors10US 9,541,553 B2Oregon Health & Science University · 2017
- CMV glycoproteins and recombinant vectors10US 9,862,972 B2Oregon Health & Science University · 2018
- CMV glycoproteins and recombinant vectors9US 10,101,329 B2Oregon Health & Science University · 2018